[{"orgOrder":0,"company":"Beta Bionics","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"||Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Beta Bionics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beta Bionics \/ Beta Bionics","highestDevelopmentStatusID":"15","companyTruncated":"Beta Bionics \/ Beta Bionics"}]

Find Clinical Drug Pipeline Developments & Deals by Beta Bionics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The collaboration aims for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

                          Product Name : Ogluo

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : Glucagon,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : Xeris Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank